The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
| Autor: | G Deslypere, J Joly, Carine Wouters, Rene Westhovens |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
musculoskeletal diseases
Pediatrics medicine.medical_specialty lcsh:Diseases of the musculoskeletal system Gastroenterology chemistry.chemical_compound Tocilizumab Refractory Rheumatology Internal medicine Medicine Immunology and Allergy In patient Pediatrics Perinatology and Child Health Young adult skin and connective tissue diseases Anakinra business.industry lcsh:RJ1-570 lcsh:Pediatrics Rash chemistry Pediatrics Perinatology and Child Health Poster Presentation Methotrexate lcsh:RC925-935 medicine.symptom business medicine.drug |
| Zdroj: | Pediatric Rheumatology Online Journal Pediatric Rheumatology Online Journal, Vol 9, Iss Suppl 1, p P137 (2011) |
| ISSN: | 1546-0096 |
| Popis: | Results Eight patients (5 women, 3 men) with a median age of 27,5yr and median disease duration of 16 yr were treated. All previously failed Methotrexate, other classical DMARD’s, 7/8 also failed on one or more biologicals (mostly TNF blockers, Anakinra in 1). Median HAQ before starting Tocilizumab was 1.25 (0.75-2.13). Tocilizumab dose was 8mg/kg/month, except for 1 patient receiving 6mg/kg/2 weeks. The median DAS-CRP decreased from 5,10(1.6-5.3) (n=6) at start to 2,25(1.32.9) (n=6) after six months (p=0,046). At 12 months, median DAS-CRP was 1,9(1.5-6.1)(n=3). Median ESR/ CRP decreased from 35(15-87)(n=6)/69,2(9.1-292.6)mg/l (n=8) at start to 2(1-7)/1,2(0.6-1.4)mg/l(n=7) at six months (p=0,028/ 0,018). At 1 year median ESR/CRP were 3,5(1-13)(n=4)/ 0,6(0.6-23.1)mg/l(n=5). A decrease/complete stop of steroids was observed in 6 patients. Atypical rash was seen in one patient, EBV-induced MAS occurred in 1 patient after 7 yrs of Tocilizumab. Conclusion Our report on young adults with persistingly active soJIA treated with Tocilizumab shows a fast, steep and persistent decrease in disease activity up to at least 1 year, demonstrating the efficacy of IL6-receptor antagonism also in patients with long-standing refractory soJIA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|